

External Quality Assessment Program for

Joint infection multiplex, nucleic acid detection

Labquality, an independent provider of External Quality Assessment (EQA) schemes with over 50 years of experience, is introducing a new scheme for Joint infection multiplex, nucleic acid detection. We are inviting a limited number of laboratories to participate in a pilot study of this new scheme free of charge. The scheme is suitable for clinical laboratories and point-of-care testing sites. The product contains selection of pathogens that may cause joint infections, e.g. *Staphylococcus aureus*, *Streptococcus agalactiae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae* complex, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Cutibacterium acnes* and *Candida albicans*. The selection will be further developed based on feedback collected during the pilot study.

The pilot study includes three simulated samples to be analysed as routine patient samples according to the established workflow of the laboratory. Results will be submitted via the online platform LabScala and processed by the EQA Coordinator.

5558 Joint infection multiplex, nucleic acid detection

- Samples:** 3 simulated samples for nucleic acid detection
- Distribution:** April 2027
- Registration:** Please register by [this link](#) or by scanning this QR code no later than 31 December 2026



For more information

Labquality's customer service info@labquality.com or

Anu Tulivuori
EQA Coordinator
anu.tulivuori@labquality.com
+358 50 406 1280

Elina Tuovinen
EQA Production Manager
elina.tuovinen@labquality.com
+358 50 361 3571